Digg!
Del.icio.usInvestor Call Scheduled for Tomorrow, Wednesday, September 7th at 11:00 a.m. EDT
Dallas, TX and New York, NY, September 06, 2011
ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced that the Company’s management team will present at the Rodman & Renshaw Annual Healthcare Conference on Monday, September 12th at 2:25p.m., in the Metropolitan West Room at the Waldorf Astoria Hotel, New York City. Jeffrey Davis, Chief Executive Officer of Access Pharmaceuticals, will give a presentation focused on the Company’s lead product for oral mucositis, MuGard and detail the development strategy for ongoing programs within its drug pipeline.
A live webcast of the presentation may be accessed by clicking on the following link: http://www.wsw.com/webcast/rrshq20/accp .To arrange a meeting with Access management at the conference, please email Christine Berni, christine.berni@accesspharma.com.
Conference Call Reminder:
The investor conference call is scheduled to be held tomorrow, Wednesday, September 7, 2011 at 11:00 am EDT. Interested parties may participate by dialing 877-407-4019 (US) or 201-689-8337 (International) approximately five to ten minutes before the call start time. A replay of the call will be available starting on September 7th at 1:00 pm EDT, through September 21, 2011 until 11:59 pm EDT. Interested parties may access the replay by dialing 877-660-6853 (US) or 201-612-7415 (International) and entering account number 383 and conference ID number 377785.
About MuGard:
MuGard is a novel; ready-to-use mucoadhesive oral wound rinse and coating for the management of oral mucositis, a debilitating side effect of many anticancer treatments. Up to 40% of all patients receiving chemotherapy and radiotherapy develop moderate to severe mucositis, and almost all patients receiving radiotherapy for head and neck cancer and those undergoing stem cell transplantation develop mucositis. Updated clinical practice guidelines for the prevention and treatment of mucositis recommend the use of a preventive oral care regimen as part of routine supportive care along with a therapeutic oral care regimen if mucositis develops. The market for the treatment of oral mucositis is estimated to be in excess of $1 billion world-wide. For more information, please visit www.MuGard.com.
About Access:
Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes proprietary products for the treatment and supportive care of cancer patients. Access’ products include MuGard™ (www.MuGard.com), which has received FDA marketing clearance for the management of patients with mucositis, ProLindac™, a second generation DACH Platinum in Phase 2 clinical testing of patients with ovarian cancer, and Thiarabine™, a novel nucleoside analog that has demonstrated both pre-clinical and clinical activity in certain cancers; currently in a Phase 1/2a trial in hematological malignancies at M.D. Anderson Cancer Center in Houston, Texas.
The company also has other advanced drug delivery technologies including CobaCyte™-mediated targeted delivery and CobOral-oral drug delivery, its proprietary nanopolymer delivery technology based on the natural vitamin B12 uptake mechanism. For additional information on Access Pharmaceuticals, please visit our website at www.accesspharma.com.
This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements include those relating to: our cash burn rate, clinical trial plans and timelines and clinical results for ProLindac, MuGard, Thiarabine and Cobalamin and other product candidates, our ability to achieve clinical and commercial success and our ability to successfully develop marketed products. These statements are subject to numerous risks, including but not limited to Access’ need to obtain additional financing in order to continue the clinical trial and operations and to the risks detailed in Access’ Annual Reports on Form 10-K and other reports filed by Access with the Securities and Exchange Commission.
MuGard's ready-to-use viscous liquid is tasteless, and is safe to swallow. See